Agreed. Looks like generic prices have bottomed given current 4 months equivalent to Jan-Apr period, but specialty brands flat on last year with increased competition on the two key brands with the bulk of the revenue is a huge concern. This fugging stock can not catch a break! So FDA approvals of generics have gone through the roof the last 2 years causing all of this additional competition, yet our approvals are no where to be seen! FFS!
Ann: 2019 AGM CEO's Speech, page-4
-
- There are more pages in this discussion • 171 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.97 |
Change
-0.130(2.55%) |
Mkt cap ! $422.8M | |||
| Open | High | Low | Value | Volume |
| $5.10 | $5.10 | $4.91 | $243.3K | 48.51K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 1442 | $4.96 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.99 | 156 | 2 |
View Market Depth
| Last trade - 10.40am 11/11/2024 (20 minute delay) ? |
| MYX (ASX) Chart |